Wall Street analysts are optimistic about Novavax's (NVAX) share price over the coming 12 months. The company is approaching the coronavirus vaccine finish line -- it aims to file for emergency authorization in various locations including the U.S. in the third quarter. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss the stock's potential as this next chapter unfolds.
10 stocks we like better than Novavax
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 7, 2021
Olivia Zitkus: Where does Wall Street, in general, where do analysts stand on this? Do you agree with them? Do you come down in a similar spot?
Adria Cimino: I think so. Novavax is trading lower than even the lowest Wall Street estimate. It's trading under $200 a share. At this point, I think with all that we can look forward to ahead. We have their catalysts, possible Emergency Use Authorization news. Of course, the application for that, and the actual authorization itself that could be catalysts. Then farther down the road, there would be the revenue once first revenue starts coming in, then the combined vaccine. There's a lot going on that I think that could drive the shares higher. I think definitely right now there's still plenty of time to buy the stock at these levels for a long-term investor.
